Leaders in molecular analysis

Pharmacogenetics, pharmacogenomics, biomarkers (ELISAs, luminescence, time resolved fluorescence), clinical chemistry, haematology, urine analysis, infectious disease screening.

Supplier to CROs (clinical trials Phase I-IV) and business to business (B2B).

Geneblitz® is the B2B molecular services division (genomics, genetics, biomarkers and haematology) of Complement Genomics Ltd. and is based at the Durham Genome Centre, Lanchester, County Durham, UK.

The company serves corporate clients (pharma, CROs) with services in genotyping (drug metabolism), next-generation sequencing (NGS), gene expression analysis, dPCR, biomarker analysis (ELISA, biochemical assays), bio-banking, haematology and urine testing and nucleic acid based microbial analysis. 

If you require biomarker or genotyping analysis for phase I – IV trials, please contact us – we have been providing such data to GCLP for many years and we have an experienced team of highly qualified scientists working to ISO 17025 and GCLP, ready to support you.

Our genotyping service offers an extensive range of assays designed to complement drug discovery, research and clinical trial programmes.

We conduct studies at all levels of the biomarker hierarchy, including DNA, mRNA, protein levels or small molecule level. We specialise in biomarker qualification and validation.

We conduct Next Generation Sequencing (NGS) for, inter alia, whole exome, whole genome, RNAseq and mitochondrial genomes.

Using Next Generation Sequencing (NGS) we offer microbiome analysis for bacterial (16S) and fungal (ITS1, ITS2) populations from any sample type.

Maintaining the highest possible sample integrity while working to GCP is the sole focus of all biological samples in our biobank.